Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Nasopharyngeal Carcinoma 16Squamous Cell Carcinoma of Head and Neck 11Esophageal Squamous Cell Carcinoma 11Esophageal Neoplasms 9Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Pancreatic cancer, adult 2Neoplasms 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Anal Canal 1Solid Tumors 1Solid Tumor 1Resectable Pancreatic Cancer 1Recurrence 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Diseases 1NSCLC 1Meningeal Carcinomatosis 1Locally Advanced Rectal Cancer 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × nimotuzumab × Clear all
NCT03388372 2018-01-03

Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

Biotech Pharmaceutical Co., Ltd.

Phase 2 Completed
39 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡